Sera Prognostics Q2 FY26 net loss widens to $9.14 million; revenue rises 76.47% to $30,000
SERA•Q2 revenue rises while loss widens
Sera Prognostics posted Q2 revenue of USD 30,000, up 76.47% from a year earlier.
Net loss widened to USD 9.14 million, or USD 0.18 a share, versus USD 8.05 million, or USD 0.16, a year earlier.
Cash position and Illinois Medicaid mandate
Cash, cash equivalents and available-for-sale securities totaled about USD 80.3 million.
Illinois enacted a Medicaid coverage mandate for prescribed proteomic blood tests.
Operating expenses increase on restructuring and commercial investments
Total operating expenses climbed to USD 10.03 million from USD 9.34 million.
- Research and development expenses rose to USD 3.49 million on restructuring-related costs.
- Selling, general and administrative expenses increased to USD 6.5 million from USD 6 million on commercial execution investments, marketing programs and strategic hires.
